Literature DB >> 31736500

Hemogenic Reprogramming of Human Fibroblasts by Enforced Expression of Transcription Factors.

Rita Silvério-Alves1, Andreia M Gomes2, Ilia Kurochkin3, Kateri A Moore4, Carlos-Filipe Pereira5.   

Abstract

The cellular and molecular mechanisms underlying specification of human hematopoietic stem cells (HSCs) remain elusive. Strategies to recapitulate human HSC emergence in vitro are required to overcome limitations in studying this complex developmental process. Here, we describe a protocol to generate hematopoietic stem and progenitor-like cells from human dermal fibroblasts employing a direct cell reprogramming approach. These cells transit through a hemogenic intermediate cell-type, resembling the endothelial-to-hematopoietic transition (EHT) characteristic of HSC specification. Fibroblasts were reprogrammed to hemogenic cells via transduction with GATA2, GFI1B and FOS transcription factors. This combination of three factors induced morphological changes, expression of hemogenic and hematopoietic markers and dynamic EHT transcriptional programs. Reprogrammed cells generate hematopoietic progeny and repopulate immunodeficient mice for three months. This protocol can be adapted towards the mechanistic dissection of the human EHT process as exemplified here by defining GATA2 targets during the early phases of reprogramming. Thus, human hemogenic reprogramming provides a simple and tractable approach to identify novel markers and regulators of human HSC emergence. In the future, faithful induction of hemogenic fate in fibroblasts may lead to the generation of patient-specific HSCs for transplantation.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31736500     DOI: 10.3791/60112

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  1 in total

Review 1.  Cellular reprogramming: Mathematics meets medicine.

Authors:  Gabrielle A Dotson; Charles W Ryan; Can Chen; Lindsey Muir; Indika Rajapakse
Journal:  Wiley Interdiscip Rev Syst Biol Med       Date:  2020-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.